Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement and atherogenesis: the unknown connection

S Bhakdi

    Annals of Medicine
    |January 27, 1999
    PubMed
    Summary
    This summary is machine-generated.

    Enzymatically degraded LDL (E-LDL), not oxidized LDL, may initiate atherosclerosis. This process triggers inflammation when the body overloads its cholesterol removal system, leading to arterial lesions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Characterization of a catalase-negative methicillin-resistant Staphylococcus aureus strain.

    Journal of clinical microbiology·2007
    Same author

    Fatty acids liberated from low-density lipoprotein trigger endothelial apoptosis via mitogen-activated protein kinases.

    Cell death and differentiation·2005
    Same author

    An hypothesis for the immunopathogenesis of atherosclerosis.

    Clinical nephrology·2003
    Same author

    [Immunopathogenesis of atherosclerosis: the Mainz hypothesis].

    Deutsche medizinische Wochenschrift (1946)·2002
    Same author

    C1-esterase-inhibitor treatment at early reperfusion of hemorrhagic shock reduces mesentry leukocyte adhesion and rolling.

    Microcirculation (New York, N.Y. : 1994)·2002
    Same author

    Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects.

    Circulation·2001
    Same journal

    Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.

    Annals of medicine·2026
    Same journal

    Postoperative outcomes of on- vs off-pump CABG in patients with HFrEF: a nationwide cohort study in Taiwan.

    Annals of medicine·2026
    Same journal

    Population pharmacokinetic-based dose adjustment of tiapride in patients with impaired renal function.

    Annals of medicine·2026
    Same journal

    Association of neutrophil percentage-to-albumin ratio with sepsis in infant.

    Annals of medicine·2026
    Same journal

    Enhancing Hemoglobin Bart's hydrops fetalis syndrome prevention: a single-tube multiplex real-time PCR assay for the comprehensive detection of four significant α<sup>0</sup>-thalassemia deletions (--<sup>SEA</sup>, --<sup>THAI</sup>, --<sup>CR</sup>, and --<sup>SA</sup>) found in Thailand.

    Annals of medicine·2026
    Same journal

    Association of non-insulin-based insulin resistance indices with the risk of aortic stenosis progression in patients with mild or moderate aortic stenosis.

    Annals of medicine·2026
    See all related articles

    Area of Science:

    • Cardiovascular Science
    • Immunology
    • Lipid Metabolism

    Background:

    • Atherosclerosis pathogenesis remains incompletely understood, with oxidized LDL (ox-LDL) and vascular infections being leading hypotheses.
    • The role of low-density lipoprotein (LDL) modification in initiating arterial inflammation has been a long-standing research question.

    Discussion:

    • This work presents evidence for enzymatically degraded LDL (E-LDL) as a key initiator of atherogenesis.
    • E-LDL activates complement and macrophages, initially aiding lipoprotein clearance but becoming detrimental when the system is overloaded.
    • This leads to a chronic inflammatory response characteristic of atherosclerotic lesions.

    Key Insights:

    • Nonoxidative, enzymatic LDL degradation transforms LDL into an atherogenic form (E-LDL).

    Related Experiment Videos

  • E-LDL triggers complement and macrophage activation, driving atherosclerotic plaque formation.
  • Chronic inflammation results from an overwhelmed cholesterol removal system due to E-LDL.

    • Outlook:

    • Further research into E-LDL's role could reveal new therapeutic targets for atherosclerosis.
    • Understanding the enzymatic modification of LDL is crucial for developing targeted interventions.
    • Investigating the interplay between E-LDL and the immune system offers avenues for novel treatment strategies.